Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.

@article{Hauser2013ExtendedreleaseC,
  title={Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.},
  author={Robert A. Hauser and Ann Hsu and Sherron H Kell and Alberto J Espay and Kapil Sethi and Mark Stacy and William G. Ondo and Martin J. O'Connell and Suneel K. Gupta},
  journal={The Lancet. Neurology},
  year={2013},
  volume={12 4},
  pages={346-56}
}
BACKGROUND IPX066 is an oral, extended-release, capsule formulation of carbidopa-levodopa. We aimed to assess this extended-release formulation versus immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations. METHODS We did a phase 3, randomised, double-blind, double-dummy study at 68 academic and clinical centres in North America and Europe. Patients with Parkinson's disease who had at least 2·5 h per day of off-time underwent 3 weeks of open-label… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.
37 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

Similar Papers

Loading similar papers…